|
| Thursday, November 14, 2024 |
|
|
Lexaria Signs Contract for New DehydraTECH GLP-1 Biodistribution Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study (the "Study"). more info >> |
|
| Wednesday, November 13, 2024 |
|
|
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). more info >> |
|
| Thursday, November 7, 2024 |
|
|
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides the following glucagon-like peptide-1 ("GLP-1") industry update. more info >> |
|
| Thursday, October 24, 2024 |
|
|
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Tuesday, October 22, 2024 |
|
|
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Thursday, October 17, 2024 |
|
|
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. more info >> |
|
| Tuesday, October 15, 2024 |
|
|
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. more info >> |
|
| Wednesday, October 9, 2024 |
|
|
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound (tirzepatide) in an oral dose format. more info >> |
|
| Tuesday, October 8, 2024 |
|
|
Lexaria Updates Current GLP-1 Market |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. more info >> |
|
| Tuesday, October 1, 2024 |
|
|
Lexaria Appoints Michael Shankman as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations. more info >> |
|
|
|
